Renin-Inhibitors Market

Renin inhibitors are one of four classes of compounds that affect the renin-angiotensin-aldosterone system. Renin inhibitors produce vasodilation by inhibiting the activity of renin, which is responsible for stimulating angiotensin II formation. Renin is a proteolytic enzyme that is released by the kidneys in response to sympathetic activation, hypotension, and decreased sodium delivery to the distal renal tubule. Aliskiren (INN) (trade names Tekturna, US; Rasilez, UK and elsewhere) is the first in a class of drugs called direct renin inhibitors. Its current licensed indication is essential (primary) hypertension.

Renin-Inhibitors Market contains market size and forecasts of Renin-Inhibitors in global, including the following market information:

Global Renin-Inhibitors Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Renin-Inhibitors Market Sales, 2017-2022, 2023-2028, (K Tablet)

Global top five Renin-Inhibitors companies in 2021 (%)

The global Renin-Inhibitors market was valued at 94 million in 2021 and is projected to reach US$ 145.6 million by 2028, at a CAGR of 6.5% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

150mg/Tablet Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Renin-Inhibitors include Novartis and Noden Pharma etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Renin-Inhibitors manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Renin-Inhibitors Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Tablet)

Global Renin-Inhibitors Market Segment Percentages, by Type, 2021 (%)

150mg/Tablet

300mg/Tablet

Global Renin-Inhibitors Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Tablet)

Global Renin-Inhibitors Market Segment Percentages, by Application, 2021 (%)

Age below 45

Age 45-55

Age 55-65

Age above 65

Global Renin-Inhibitors Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Tablet)

Global Renin-Inhibitors Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Renin-Inhibitors revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Renin-Inhibitors revenues share in global market, 2021 (%)

Key companies Renin-Inhibitors sales in global market, 2017-2022 (Estimated), (K Tablet)

Key companies Renin-Inhibitors sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Novartis

Noden Pharma